NCT06561542招募中1 期
A Phase I, Escalating Single and Multiple Dose Study of LX22001 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Bioavailability in Healthy Subjects.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- Number of Participants With Adverse Events
研究概览
简要总结
Study to evaluate the safety and tolerability, pharmacokinetics/pharmacodynamics (PK/PD) parameters of an escalating, single dose/repeat doses of LX22001 for injection in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects who fully understand the objectives, nature, methods and possible AEs of the study, voluntarily participate in the clinical study, and sign the Informed Consent Form (ICF) before the initiation of any study procedure, and warrant that any study procedure will be participated in by themselves;
- •Healthy Chinese subjects aged 18-45 years (inclusive, at the date of signing the ICF), both males and females;
- •Body mass index (BMI): 19.0-26.0 kg/m2 (inclusive); weight: ≥ 50 kg for male and ≥ 45 kg for female;
- •Subjects who are willing to use effective contraception and have no sperm or egg donation plan from the time of signing the informed consent form until 3 months after the last dose (see Appendix 20.1 for details of contraceptive measures and contraceptive requirements);
- •Subjects who can communicate well with the investigator, and understand and comply with the requirements of this study."
排除标准
- •Allergy (such as: allergic to two or more drugs, foods, or pollen), history of atopic allergic disease (such as: asthma, urticaria, eczematous dermatitis, etc.), history of allergy to any of the components and excipients of the study drugs (LX22001 for injection, tegoprazan tablets, and Esomeprazole Sodium for injection), or allergy to penicillin, cephalosporin, and other antibiotics;
- •Any disease or history of disease that may significantly affect drug absorption, distribution, metabolism, and excretion, or any condition that may pose a hazard to the subject, such as: inflammatory bowel disease, gastric ulcer, duodenal ulcer, gastrointestinal/rectal bleeding, persistent nausea, or other clinically significant gastrointestinal anomalies; history of major gastrointestinal surgery (such as: gastrectomy, gastrointestinal anastomosis, bowel resection, gastric bypass, gastric banding, cholecystectomy, except for appendicitis surgery and prolapse surgery);
- •History of chronic or serious illness or present illness of cardiovascular, hepatic, renal, respiratory, hematologic and lymphatic, endocrine, immunologic, psychiatric, neurologic, gastrointestinal, metabolic, and skeletal systems within the last 1 year;
- •Clinically significant abnormalities in physical examination and laboratory tests at screening, judged by the investigators;
- •For those with clinically significant abnormalities in vital signs at screening which will be judged by the investigators based on the actual situations;
- •The serological virology test shows positive results of HIV antigen antibody (HIV-Ag/Ab), hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), or treponema pallidum antibody (TP-Ab) at screening;
- •Women who have not taken effective contraception within 15 days prior to the screening period, or have a positive blood pregnancy test or are breastfeeding during the screening period;
- •Those who have a history of drug abuse within the past five years or drug use in the three months prior to screening, or positive results for urine drug test during the screening period;
- •Those who smoke more than 5 cigarettes per day or had a habit of using nicotine-containing products within 3 months prior to screening, or test positive for nicotine test at screening;
- •Those who drink more than 14 units of alcohol per week (1 unit of alcohol = 360 mL of beer or 45 mL of ABV 40% spirit or 150 mL of wine) within 3 months prior to screening or have consumed an alcohol-containing product 48h prior to the dose or test positive for alcohol breath test at screening;
- •Those who have used any medication (including prescription, over-the-counter, nutritional supplements, Chinese herbal medicine, vitamins, etc.) or are on medication within 1 month prior to screening;
- •Those who have participated in other clinical studies and used other investigational drugs or interventional therapies within 3 months prior to screening;
- •Those who have donated or lost more than 200 mL of blood or received blood transfusion or used blood products within 3 months prior to screening;
- •Those who have consumed any food or beverage containing caffeine or producing caffeine or xanthine metabolites (e.g., coffee, tea, chocolate) within 48h prior to the dose;
- •Those who have consumed grapefruit, limes, carambola,pitaya, mango or food or drinks prepared from them within 7 days prior to screening;
- •Those who are unable to establish intravenous access or intolerable to intravenous administration;
- •Those who are involved in the planning and execution of this study;
- •Any other circumstance that, in the opinion of the investigator, the subject may be hindered from providing informed consent or following the protocol, or the subject's participation in the study may affect the results of the study or his or her own safety."
研究组 & 干预措施
LX22001 for Injecton
Experimental
干预措施: LX22001 for Injeciton (Drug)
Tegoprazan tablet
Active Comparator
干预措施: Tegoprazan tablet (Drug)
Esomeprazole sodium for injection
Active Comparator
干预措施: Esomeprazole sodium for injection (Drug)
结局指标
主要结局
Number of Participants With Adverse Events
时间窗: 7 days from dosing
次要结局
- Apparent volume of distribution(Vd)(pre-dose to Day1 post-dose)
- Area Under the Concentration-Time Curve From Time 0 to the 24-Hour Time Point (AUC0-24)(pre-dose to Day1 post-dose)
- Apparent total body clearance (CL)(pre-dose to Day1 post-dose)
- Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) at Steady State(Day 3 post-dose)
- Percentage of Time Gastric pH above 4 over 24h(baseline, Day 1 and Day 3)
- Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf)(pre-dose to Day1 post-dose)
- Maximum Observed Plasma Concentration (Cmax)(pre-dose to Day1 post-dose)
- Terminal elimination half-life(t1/2)(pre-dose to Day1 post-dose)
- Cmax at Steady State (Cmax,ss)(Day 3 post-dose)
- Percentage of Time Gastric pH above 6 over 24h(baseline, Day 1 and Day 3)
- Mean Gastric pH over 24h(baseline, Day 1 and Day 3)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)Hemophilia AHealthy ParticipantsHemophilia AHemophilia BHemophilia BNCT06349473Equilibra Bioscience LLC31
已完成
1 期
Study of ARO-AAT in Normal Adult VolunteersAlpha 1-Antitrypsin DeficiencyNCT03362242Arrowhead Pharmaceuticals45
已完成
1 期
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)Familial ChylomicronemiaHypertriglyceridemiaNCT03783377Arrowhead Pharmaceuticals112
已完成
1 期
A Study of STSP-0902 Ophthalmic Solution in Healthy SubjectsNeurotrophic KeratitisNCT06597422Staidson (Beijing) Biopharmaceuticals Co., Ltd82
已完成
1 期
Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASHNon-alcoholic SteatohepatitisNCT04202354Arrowhead Pharmaceuticals50